Recent studies have shed light on the dual nature of GLP-1 receptor agonists, such as semaglutide and Ozempic, revealing both potential therapeutic benefits and risks for musculoskeletal health. While these medications may reverse damage caused by osteoarthritis and alleviate arthritis pain in some patients, they are also linked to an increased risk of osteoporosis and gout. Researchers are exploring the impact of these drugs on chronic pain management, with some findings suggesting that pain in osteoarthritis may decrease significantly within days of starting treatment, even before any weight loss occurs. This raises questions about the mechanisms at play within the joints and the long-term implications of GLP-1 usage on orthopedic surgical outcomes.